Pancreatic cancer is one of the most lethal cancers. In the US, it accounts for about 3% of all cancers and about 7% of all cancer deaths. Patients seldom exhibit symptoms until an advanced stage of the disease. Surgery remains the most effective treatment of pancreatic cancer with a 61% difference in 5-year survival between surgery eligible and ineligible patients. Unfortunately, even when the cancer remains localized at time of diagnosis, ~2/3 of patients are ineligible for surgery because their cancer encases vital structures, such as the superior mesenteric artery. Padeliporfin VTP therapy is currently being evaluated for this indication as a means to bridge more patients to surgery.